Patients with or without HF: 1 trials - GLOBAL
| irbesartan vs control | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Death from any cause or hospitalization for any reason | no data | | NYHA class improvement | no data | | death or severe congestive heart failure | no data | | Long term death | no data | | hospitalisation for heart failure | no data | | All cause death | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Systematic early treatment (with or without sign of HF): 1 trials - GLOBAL
| irbesartan vs control | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Death from any cause or hospitalization for any reason | no data | | NYHA class improvement | no data | | death or severe congestive heart failure | no data | | Long term death | no data | | hospitalisation for heart failure | no data | | All cause death | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Patient with history of atrial fibrillation: 2 trials - ACTIVE I - Madrid
| irbesartan vs control | No demonstrated result suggested atrial fibrillation recurrence by 61% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | Vascular death | no data | | atrial fibrillation recurrence | 0.39 [0.17 0.91] | p=0.04 | 0 | 154 | 1 | Madrid, | | more than one AF recurrence | no data | | Vascular events | no data | | hospitalisation for heart failure | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| irbesartan vs placebo | No demonstrated result suggested hospitalisation for heart failure by 13% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| myocardial infarction (fatal and non fatal) | 1.05 [0.83 1.34] | p=1.00 | 0 | 9016 | 1 | ACTIVE I, | | stroke (fatal and non fatal) | 0.92 [0.80 1.07] | p=1.00 | 0 | 9016 | 1 | ACTIVE I, | | Vascular death | 1.03 [0.91 1.15] | p=1.00 | 0 | 9016 | 1 | ACTIVE I, | | atrial fibrillation recurrence | no data | | more than one AF recurrence | no data | | Vascular events | 1.00 [0.90 1.10] | p=1.00 | 0 | 9016 | 1 | ACTIVE I, | | hospitalisation for heart failure | 0.87 [0.76 0.99] | p=0.04 | 0 | 9016 | 1 | ACTIVE I, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
All type of patients: 3 trials - IPDM (150mg) - IDNT (irbesartan vs pbo) - IDNT (irbesartan vs amlodipine)
| irbesartan vs amlodipine | No demonstrated result suggested microvascular events by 23% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | 1.03 [0.81 1.31] | p=1.00 | 0 | 1146 | 1 | IDNT (irbesartan vs amlodipine), | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | microvascular events | 0.77 [0.63 0.94] | p=0.04 | 0 | 1146 | 1 | IDNT (irbesartan vs amlodipine), | | Non fatal MI | no data | | All cause death | 1.04 [0.77 1.40] | p=1.00 | 0 | 1146 | 1 | IDNT (irbesartan vs amlodipine), | | Non fatal stroke | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| irbesartan vs placebo | No demonstrated result suggested microvascular events by 25% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | 0.91 [0.72 1.15] | p=1.00 | 0 | 1148 | 1 | IDNT (irbesartan vs pbo), | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | microvascular events | 0.75 [0.63 0.91] | p=0.04 | 0 | 1738 | 2 | IPDM (150mg),IDNT (irbesartan vs pbo), | | Non fatal MI | no data | | All cause death | 0.92 [0.69 1.23] | p=1.00 | 0 | 1148 | 1 | IDNT (irbesartan vs pbo), | | Non fatal stroke | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Patients with hypertension: 3 trials - IPDM (150mg) - IDNT (irbesartan vs pbo) - IDNT (irbesartan vs amlodipine)
| irbesartan vs amlodipine | No demonstrated result suggested microvascular events by 23% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | 1.03 [0.81 1.31] | p=1.00 | 0 | 1146 | 1 | IDNT (irbesartan vs amlodipine), | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | microvascular events | 0.77 [0.63 0.94] | p=0.04 | 0 | 1146 | 1 | IDNT (irbesartan vs amlodipine), | | Non fatal MI | no data | | All cause death | 1.04 [0.77 1.40] | p=1.00 | 0 | 1146 | 1 | IDNT (irbesartan vs amlodipine), | | Non fatal stroke | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| irbesartan vs placebo | No demonstrated result suggested microvascular events by 25% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | 0.91 [0.72 1.15] | p=1.00 | 0 | 1148 | 1 | IDNT (irbesartan vs pbo), | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | microvascular events | 0.75 [0.63 0.91] | p=0.04 | 0 | 1738 | 2 | IPDM (150mg),IDNT (irbesartan vs pbo), | | Non fatal MI | no data | | All cause death | 0.92 [0.69 1.23] | p=1.00 | 0 | 1148 | 1 | IDNT (irbesartan vs pbo), | | Non fatal stroke | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Patients with or without hypertension: 3 trials - IPDM (150mg) - IDNT (irbesartan vs pbo) - IDNT (irbesartan vs amlodipine)
| irbesartan vs amlodipine | No demonstrated result suggested microvascular events by 23% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | 1.03 [0.81 1.31] | p=1.00 | 0 | 1146 | 1 | IDNT (irbesartan vs amlodipine), | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | microvascular events | 0.77 [0.63 0.94] | p=0.04 | 0 | 1146 | 1 | IDNT (irbesartan vs amlodipine), | | Non fatal MI | no data | | All cause death | 1.04 [0.77 1.40] | p=1.00 | 0 | 1146 | 1 | IDNT (irbesartan vs amlodipine), | | Non fatal stroke | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| irbesartan vs placebo | No demonstrated result suggested microvascular events by 25% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | 0.91 [0.72 1.15] | p=1.00 | 0 | 1148 | 1 | IDNT (irbesartan vs pbo), | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | microvascular events | 0.75 [0.63 0.91] | p=0.04 | 0 | 1738 | 2 | IPDM (150mg),IDNT (irbesartan vs pbo), | | Non fatal MI | no data | | All cause death | 0.92 [0.69 1.23] | p=1.00 | 0 | 1148 | 1 | IDNT (irbesartan vs pbo), | | Non fatal stroke | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
All type of patients: 3 trials - IPDM (150mg) - IDNT (irbesartan vs pbo) - IDNT (irbesartan vs amlodipine)
| irbesartan vs amlodipine | No demonstrated result suggested microvascular events by 23% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | 1.03 [0.81 1.31] | p=1.00 | 0 | 1146 | 1 | IDNT (irbesartan vs amlodipine), | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | microvascular events | 0.77 [0.63 0.94] | p=0.04 | 0 | 1146 | 1 | IDNT (irbesartan vs amlodipine), | | Non fatal MI | no data | | All cause death | 1.04 [0.77 1.40] | p=1.00 | 0 | 1146 | 1 | IDNT (irbesartan vs amlodipine), | | Non fatal stroke | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| irbesartan vs placebo | No demonstrated result suggested microvascular events by 25% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | 0.91 [0.72 1.15] | p=1.00 | 0 | 1148 | 1 | IDNT (irbesartan vs pbo), | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | microvascular events | 0.75 [0.63 0.91] | p=0.04 | 0 | 1738 | 2 | IPDM (150mg),IDNT (irbesartan vs pbo), | | Non fatal MI | no data | | All cause death | 0.92 [0.69 1.23] | p=1.00 | 0 | 1148 | 1 | IDNT (irbesartan vs pbo), | | Non fatal stroke | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
All type of patients: 1 trials - Tonkon et al.
| irbesartan+ACE inhibitor vs ACE inhibitor only | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Sudden death | no data | | Death from any cause or hospitalization for any reason | no data | | Cardiovascular death or hospital admission for CHF | no data | | death or cardiovascular hospitalization | no data | | Cardiovascular death | no data | | hospitalisation for heart failure | no data | | Hospitalization for any reason | no data | | no data | | Hyperkalaemia | no data | | Cough | no data | | Hypotension | no data | | angiodema | no data | | Adverse events | no data | | All cause death | 0.91 [0.02 46.82] | p=1.00 | 0 | 109 | 1 | Tonkon et al., |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Patients already receiving ACE inhibitor: 1 trials - Tonkon et al.
| irbesartan+ACE inhibitor vs ACE inhibitor only | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Sudden death | no data | | Death from any cause or hospitalization for any reason | no data | | Cardiovascular death or hospital admission for CHF | no data | | death or cardiovascular hospitalization | no data | | Cardiovascular death | no data | | hospitalisation for heart failure | no data | | Hospitalization for any reason | no data | | no data | | Hyperkalaemia | no data | | Cough | no data | | Hypotension | no data | | angiodema | no data | | Adverse events | no data | | All cause death | 0.91 [0.02 46.82] | p=1.00 | 0 | 109 | 1 | Tonkon et al., |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Patients with preserved-LVEF heart failure : 1 trials - I-PRESERVE (McMurray)
| ibesartan vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Sudden death | no data | | Death from any cause or hospitalization for any reason | no data | | Cardiovascular death or hospital admission for CHF | 0.97 [0.84 1.13] | p=1.00 | 0 | 4128 | 1 | I-PRESERVE (McMurray), | | death or cardiovascular hospitalization | 0.97 [0.85 1.10] | p=1.00 | 0 | 4128 | 1 | I-PRESERVE (McMurray), | | Cardiovascular death | 1.03 [0.86 1.22] | p=1.00 | 0 | 4128 | 1 | I-PRESERVE (McMurray), | | hospitalisation for heart failure | 0.96 [0.82 1.14] | p=1.00 | 0 | 4128 | 1 | I-PRESERVE (McMurray), | | Hospitalization for any reason | 1.02 [0.90 1.15] | p=1.00 | 0 | 4128 | 1 | I-PRESERVE (McMurray), | | no data | | Hyperkalaemia | no data | | Cough | no data | | Hypotension | no data | | angiodema | no data | | Adverse events | no data | | All cause death | 1.02 [0.88 1.18] | p=1.00 | 0 | 4128 | 1 | I-PRESERVE (McMurray), |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
All type of patients: 1 trials - I-PRESERVE (McMurray)
| ibesartan vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Sudden death | no data | | Death from any cause or hospitalization for any reason | no data | | Cardiovascular death or hospital admission for CHF | 0.97 [0.84 1.13] | p=1.00 | 0 | 4128 | 1 | I-PRESERVE (McMurray), | | death or cardiovascular hospitalization | 0.97 [0.85 1.10] | p=1.00 | 0 | 4128 | 1 | I-PRESERVE (McMurray), | | Cardiovascular death | 1.03 [0.86 1.22] | p=1.00 | 0 | 4128 | 1 | I-PRESERVE (McMurray), | | hospitalisation for heart failure | 0.96 [0.82 1.14] | p=1.00 | 0 | 4128 | 1 | I-PRESERVE (McMurray), | | Hospitalization for any reason | 1.02 [0.90 1.15] | p=1.00 | 0 | 4128 | 1 | I-PRESERVE (McMurray), | | no data | | Hyperkalaemia | no data | | Cough | no data | | Hypotension | no data | | angiodema | no data | | Adverse events | no data | | All cause death | 1.02 [0.88 1.18] | p=1.00 | 0 | 4128 | 1 | I-PRESERVE (McMurray), |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
All diseases requiring ACEi (HF, CHD, HT,...): 2 trials - IDNT (irbesartan vs pbo) - IRMA 2
| irbesartan vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | 1.11 [0.73 1.68] | p=1.00 | 0 | 1148 | 1 | IDNT (irbesartan vs pbo), | | myocardial infarction (fatal and non fatal) | 0.88 [0.59 1.32] | p=1.00 | 0 | 1759 | 2 | IDNT (irbesartan vs pbo),IRMA 2, | | stroke (fatal and non fatal) | 1.06 [0.61 1.83] | p=1.00 | 0 | 1148 | 1 | IDNT (irbesartan vs pbo), | | Coronary event | 0.91 [0.72 1.15] | p=1.00 | 0 | 1148 | 1 | IDNT (irbesartan vs pbo), | | cardiac death | no data | | cancer related death | no data | | Heart failure | 0.82 [0.57 1.18] | p=1.00 | 0 | 1148 | 1 | IDNT (irbesartan vs pbo), | | All cause death | 0.93 [0.69 1.27] | p=1.00 | 0 | 1759 | 2 | IDNT (irbesartan vs pbo),IRMA 2, | | lung cancer | no data | | breast cancer | no data | | prostate cancer | no data | | Cancer | no data | | Diabetes onset | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
All type of patient: 2 trials - IDNT (irbesartan vs pbo) - IRMA 2
| irbesartan vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | 1.11 [0.73 1.68] | p=1.00 | 0 | 1148 | 1 | IDNT (irbesartan vs pbo), | | myocardial infarction (fatal and non fatal) | 0.88 [0.59 1.32] | p=1.00 | 0 | 1759 | 2 | IDNT (irbesartan vs pbo),IRMA 2, | | stroke (fatal and non fatal) | 1.06 [0.61 1.83] | p=1.00 | 0 | 1148 | 1 | IDNT (irbesartan vs pbo), | | Coronary event | 0.91 [0.72 1.15] | p=1.00 | 0 | 1148 | 1 | IDNT (irbesartan vs pbo), | | cardiac death | no data | | cancer related death | no data | | Heart failure | 0.82 [0.57 1.18] | p=1.00 | 0 | 1148 | 1 | IDNT (irbesartan vs pbo), | | All cause death | 0.93 [0.69 1.27] | p=1.00 | 0 | 1759 | 2 | IDNT (irbesartan vs pbo),IRMA 2, | | lung cancer | no data | | breast cancer | no data | | prostate cancer | no data | | Cancer | no data | | Diabetes onset | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Diabetic patients : 4 trials - IPDM (150mg) - IDNT (irbesartan vs pbo) - IDNT (irbesartan vs amlodipine) - IRMA 2
| irbesartan vs amlodipine | No demonstrated result suggested microvascular events by 23% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | 1.03 [0.81 1.31] | p=1.00 | 0 | 1146 | 1 | IDNT (irbesartan vs amlodipine), | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | microvascular events | 0.77 [0.63 0.94] | p=0.04 | 0 | 1146 | 1 | IDNT (irbesartan vs amlodipine), | | Non fatal MI | no data | | All cause death | 1.04 [0.77 1.40] | p=1.00 | 0 | 1146 | 1 | IDNT (irbesartan vs amlodipine), | | Non fatal stroke | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| irbesartan vs placebo | No demonstrated result suggested microvascular events by 25% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | 0.91 [0.72 1.15] | p=1.00 | 0 | 1148 | 1 | IDNT (irbesartan vs pbo), | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | 0.51 [0.15 1.79] | p=1.00 | 0 | 611 | 1 | IRMA 2, | | stroke (fatal and non fatal) | no data | | Coronary event | no data | | cardiac death | no data | | microvascular events | 0.75 [0.63 0.91] | p=0.04 | 0 | 1738 | 2 | IPDM (150mg),IDNT (irbesartan vs pbo), | | cancer related death | no data | | Non fatal MI | no data | | Heart failure | no data | | All cause death | 0.93 [0.71 1.23] | p=1.00 | 0 | 1759 | 2 | IDNT (irbesartan vs pbo),IRMA 2, | | Non fatal stroke | no data | | lung cancer | no data | | breast cancer | no data | | prostate cancer | no data | | Cancer | no data | | Diabetes onset | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Nephropathy: 1 trials - IDNT (irbesartan vs pbo)
| irbesartan vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | 1.11 [0.73 1.68] | p=1.00 | 0 | 1148 | 1 | IDNT (irbesartan vs pbo), | | myocardial infarction (fatal and non fatal) | 0.94 [0.61 1.45] | p=1.00 | 0 | 1148 | 1 | IDNT (irbesartan vs pbo), | | stroke (fatal and non fatal) | 1.06 [0.61 1.83] | p=1.00 | 0 | 1148 | 1 | IDNT (irbesartan vs pbo), | | Coronary event | 0.91 [0.72 1.15] | p=1.00 | 0 | 1148 | 1 | IDNT (irbesartan vs pbo), | | cardiac death | no data | | cancer related death | no data | | Heart failure | 0.82 [0.57 1.18] | p=1.00 | 0 | 1148 | 1 | IDNT (irbesartan vs pbo), | | All cause death | 0.92 [0.67 1.26] | p=1.00 | 0 | 1148 | 1 | IDNT (irbesartan vs pbo), | | lung cancer | no data | | breast cancer | no data | | prostate cancer | no data | | Cancer | no data | | Diabetes onset | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
All type of patients: 2 trials - IDNT (irbesartan vs pbo) - IRMA 2
| irbesartan vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | 1.11 [0.73 1.68] | p=1.00 | 0 | 1148 | 1 | IDNT (irbesartan vs pbo), | | myocardial infarction (fatal and non fatal) | 0.88 [0.59 1.32] | p=1.00 | 0 | 1759 | 2 | IDNT (irbesartan vs pbo),IRMA 2, | | stroke (fatal and non fatal) | 1.06 [0.61 1.83] | p=1.00 | 0 | 1148 | 1 | IDNT (irbesartan vs pbo), | | Coronary event | 0.91 [0.72 1.15] | p=1.00 | 0 | 1148 | 1 | IDNT (irbesartan vs pbo), | | cardiac death | no data | | cancer related death | no data | | Heart failure | 0.82 [0.57 1.18] | p=1.00 | 0 | 1148 | 1 | IDNT (irbesartan vs pbo), | | All cause death | 0.93 [0.69 1.27] | p=1.00 | 0 | 1759 | 2 | IDNT (irbesartan vs pbo),IRMA 2, | | lung cancer | no data | | breast cancer | no data | | prostate cancer | no data | | Cancer | no data | | Diabetes onset | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
